IntellxxDNA Conference Agenda

Longevity: What Do We Learn from the Blue Zones and Other Centenarians?

Sharon Hausman-Cohen, MD

In this talk, some of the top gene variants associated with longevity will be explored including Klotho, FOXO3, ApoE2, G6PD, and TERC—a new IntellxxDNA longevity SNP. As we study the genomics of the Blue Zones and other centenarians, we realize there are many different genomic pathways that can threaten healthy longevity, and can help you guide your patients in optimizing aging with diet, lifestyle, supplements, and even peptides.

Diabesity: GLP-1s and Beyond from a Genomic Standpoint

Aunna Herbst, DO

What do we do when GLP-1s do not fix it? Fifteen percent of individuals don’t respond to GLP-1s—and not everyone wants to be on one—so how do you address diabetes and obesity with specificity? By understanding root-cause genomic variants such as TCF7L2, GLP1R, FTO, and PPARGC1, you can offer patients more information about their likelihood of response to GLP-1s as well as how to address these health issues with other options.

Introducing Lexxi — The Newest Addition to the IntellxxDNA Team

Carol Bilich, Sharon Hausman-Cohen, MD – IntellxxDNA Co-Founders

Lexxi is going to make using IntellxxDNA fast and easy! Lexxi is our new assistant that will help you find the SNPs most relevant to your patient’s concerns, allow you to select them with a few clicks, and will even write a synopsis of what these gene variants do and how they relate to your patient’s concerns. You can ask Lexxi questions to take your understanding to deeper levels or go broad and explore more concerns. Once you have chosen the SNPs you want to discuss, Lexxi can write a draft of your patient plan for you to accept or edit. Lexxi will even show you the most relevant potential interventions and help you prepare them in a patient-friendly list. Lexxi is not linked to an open AI system, so it cannot hallucinate or give you bad data—and it has an extensive supporting knowledge matrix to help you understand the role of patient fundamentals such as oxidative stress, detox, inflammation, nutrients, and gut issues in the context of patient concerns.

A Closer Look at How Genomics Can Improve Treatment

Kristine Burke, MD

By taking a look at some of the Evanthea data (a study designed by Dr. Dale Bredesen with primary investigators including Kat Toups, Kristine Burke, Craig Tanio, et al.), we can learn from Dr. Burke’s successes and approach—seeing how she uses genomics alongside patient labs, test scores, and history to guide a patient toward a plan that supports brain health. Dr. Burke will discuss Tau testing and other modalities she uses to monitor progress, as well as her approach to supplementation and support.

One Kidney Is Starting to Go

Eleanor Womack & Theresa Pugh

Renal dysfunction is rarely caused by a single issue—it is the result of multiple overlapping pathways that are often missed in traditional evaluation. Follow along as we walk through a patient with declining kidney function and uncover key contributors, including oxidative stress, detoxification pathways, inflammation, endothelial dysfunction, and hypercoagulability. You will see how genomics helps connect these pathways to clinical outcomes and guides targeted, root-cause interventions. This session emphasizes practical application, showing how to prioritize findings and translate complex genomic data into meaningful clinical strategies.

Irreplaceable: Building Your Brand

JJ Virgin

In an era where AI can generate content, interpret labs, and replicate clinical knowledge in seconds, information alone is no longer a competitive advantage. Trust is. At the same time, the health and wellness landscape has become increasingly crowded and commoditized—from functional medicine and longevity to weight loss, hormones, and regenerative care. The practices and brands that continue to grow are not those with the most content, credentials, or ad spend, but those that are unmistakably differentiated.

Reading Between the SNPs: How Genomics Exposed the Aspirin–MCAS–TILT Connection in a Complex Multisystem Patient

Jessica Knape, MD

This session will walk through a compelling case of a patient with lifelong pesticide exposure whose genome reflects impaired detoxification and heightened inflammatory reactivity. Homozygous GSTM1, along with GSTP1 and PON1 variants, contributed to reduced capacity to clear organophosphates, heavy metals, and other accumulated toxicants, creating a foundation for Toxicant-Induced Loss of Tolerance (TILT). With additional variants in IL-1β, IL-6, and CXCL8, each exposure—whether infectious, environmental, or chemical—triggers a disproportionate and prolonged inflammatory response. The discussion will also examine how genomically driven susceptibilities, including mast cell activation and food sensitivities, shaped her clinical presentation and progression to MCAS. Particular attention will be given to how common interventions, such as daily aspirin, may act as ongoing triggers in susceptible individuals.

Cognition Study Update — Results from a Genomically Targeted Study in Adults in Psychiatric Residential Care

Andrea Ianuzzelli

Asthma, Recurrent Sinus and Lung Infections

Emily Gutierrez, DNP

Super Anxious: Is It Hypomania or High Cortisol?

Jennifer Kraker, MD

Corty is a case of a woman with anxiety, bipolar disorder, and IBS (constipation prone). This case will allow us to get to know a new gene variant, NR3C2, that regulates the HPA axis and can contribute to hypercortisolism. Could this be part of the “bipolar” diagnosis along with high-glutamate SNPs?

Introducing Lexxi — The Newest Addition to the IntellxxDNA Team

Carol Bilich, Sharon Hausman-Cohen, MD – IntellxxDNA Co-Founders

Lexxi is going to make using IntellxxDNA fast and easy! Lexxi is our new assistant that will help you find the SNPs most relevant to your patient’s concerns, allow you to select them with a few clicks, and will even write a synopsis of what these gene variants do and how they relate to your patient’s concerns. You can ask Lexxi questions to take your understanding to deeper levels or go broad and explore more concerns. Once you have chosen the SNPs you want to discuss, Lexxi can write a draft of your patient plan for you to accept or edit. Lexxi will even show you the most relevant potential interventions and help you prepare them in a patient-friendly list. Lexxi is not linked to an open AI system, so it cannot hallucinate or give you bad data—and it has an extensive supporting knowledge matrix. Guaranteed.

GCH1: From ADHD and Anxiety to Self-Injurious Behavior

Sharon Hausman-Cohen, MD

Alcohol Use Disorder and Glutathione

Jennifer Kraker, MD

Description to be announced.

New Approach to Gut and Autoimmune

Aunna Herbst, DO

Histamine intolerance, low zonulin, TNFα, HLA, and MBL2 can all contribute to gut inflammation, autoimmune disease, gut permeability, and neuroinflammation. Understanding which of these are the driving forces in your patient can change management for inflammatory immune dysfunction, whether using diet, peptides, or supplements.

Graves’ and Other Autoimmune Disease: How Can We Help?

Theresa Pugh, MD

This talk covers Graves’ disease, improving thyroid levels, and lowering antibody levels in patients with Graves’, as well as helping to reverse autoimmune conditions in other patients. Includes guidance on stopping cat’s claw, which can cause harm to the kidneys.

Interventions Update: PQQ, Lactoferrin, Plasmalogens, and More

David Socol, MD

An update on how various interventions work and interact with genomics. Description to be announced.